# Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

> **NCT02668640** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 55 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT02668640
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-01
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-08-13
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02668640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02668640, "Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02668640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*